Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Continuous Lenalidomide in Nontransplanted MM, The FIRST Trial

Bor/Len/Dex vs Len/Dex: SWOG S0777 Data 3-Drug Regimen as Initial Induction

Maintenance Therapy: The Nurse’s Role

Multiple Myeloma Plasma Cell Malignancy

Diagnostic Criteria MM Requiring Therapy

Maintenance Lenalidomide Key Trials

Meta-Analysis Results of Maintenance Lenalidomide

Risk Stratification

Bortezomib in the Maintenance Setting

HOVON-65/GMMG-HD4: Bortezomib Induction and Maintenance by Cytogenetic Risk

IFM 2009 Study ASCT vs No ASCT

Ixazomib vs Placebo Following ASCT in Newly Diagnosed MM, Phase 3 Tourmaline-MM3 Trial

Cytogenetic Risk Features

RVD Maintenance Therapy After ASCT

Communicating With Patients

Be Prepared for Complex Questions

Tools for Optimizing Adherence

Monitoring Patients After Initial Therapy Asymptomatic, Nonprogressing

Toxicities and Maintenance Therapy

Select Adverse Events and Prophylaxis by Drug Class

Bone-Modifying Agents

Key Takeaways for Nurses

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)